Side Effects Blog

This article, “New-Onset Nonarteritic Anterior Ischemic Optic Neuropathy and Initiators of Semaglutide in US Veterans With Type 2 Diabetes”, published in February 2026 by the medical journal JAMA Ophthalmology, begins with a “Key Points” part that includes the following:

Question Is semaglutide associated with an increased risk of incidence of nonarteritic anterior ischemic optic neuropathy (NAION) compared with sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with type 2 diabetes?

Findings In this study, among a group of US veterans with type 2 diabetes, initiation of semaglutide was associated with a 2-fold higher risk of incident NAION compared with initiation of an SGLT2i,…

In addition to Ozempic, two other semaglutide-containing drugs are Wegovy and Rybelsus, so this new evidence about the Ozempic NAION risk applies to those drugs, also. We point out that Novo Nordisk is the pharmaceutical company responsible for Ozempic, Wegovy, and Rybelsus.

Here are some of the earlier posts relevant to this recently reported medical fact that the Ozempic NAION risk 200% higher than that of some other diabetes drugs:

• Ozempic NAION Rate Higher in Recent 2025 Medical Study
• Link Between Ozempic and NAION Also Involves the Eye Disorder AION
• Vision Loss Linked to Ozempic and Rybelsus Use by Diabetes Patients
• Ozempic Eye Problems Caused by Semaglutide-Related NAION
• Ozempic Linked to Vision Loss With Increased Risk of NAION Side Effect
• Ozempic Side Effects Include Eye Problems With Possible Vision Loss

The current drug labels for Ozempic, Wegovy, and Rybelsus do not warn about non-arteritic anterior ischemic optic neuropathy (NAION)as a possible eye-related side effect that can cause vision loss.

Given that situation, together with newly reported evidence of the Ozempic NAION risk 200% higher than that of some other diabetes drugs, we are handling drug injury lawsuits for patients who developed the NAION eye-related side effect associated with Ozempic, Wegovy, and Rybelsus.

Drug injury lawsuits involving Ozempic, Wegovy, and Rybelsus for patients diagnosed with NAION would be filed against Novo Nordisk for its failure to warn about NAION as a possible side effect.

If you have a possible Rybelsus, Wegovy, or Ozempic NAION case that you would like to have investigated for a drug injury lawsuit, you can submit an online Case Evaluation Form. If you prefer, send attorney Tom Lamb an email (TJL@LambLawOffice.com) or call him (910-256-2971)..

5.2 Acute Pancreatitis

Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including RYBELSUS [see Adverse Reactions (6)]. After initiation of RYBELSUS, observe patients carefully for signs and symptoms of pancreatitis, which may include persistent or severe abdominal pain (sometimes radiating to the back), and which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, discontinue RYBELSUS and initiate appropriate management.

We are investigating Rybelsus pancreatitis drug injury lawsuits, with a focus on cases of hemorrhagic pancreatitis or necrotizing pancreatitis involving death. Those Rybeslus pancreatitis death cases would be filed against the responsible pharmaceutical company, Novo Nordisk.

The best possible Rybelsus pancreatitis drug injury lawsuits would be for people who were diagnosed with pancreatitis before October 2025 because, as indicated above, those cases could include a “failure to warn” legal allegation against the drug company Novo Nordisk.

And cases of hemorrhagic pancreatitis or necrotizing pancreatitis involving death would be the most significant Rybelsus drug injury lawsuits in terms of legal compensation and liability, and better than those cases where the pancreatitis went away after a person stopped using Rybelsus.

Finally, cases involving acute pancreatitis diagnosed after October 2025 while using Rybelsus are less likely to be filed as drug injury lawsuits against Novo Nordisk due to the Rybelsus drug label change above that added the pancreatitis drug side-effect warnings.

If you have a possible Rybelsus pancreatitis drug injury lawsuit that you would like to have investigated by drug injury attorney Tom Lamb, you can submit an online Case Evaluation Form. If you prefer, send him an email (TJL@LambLawOffice.com) or call him (910-256-2971).

We want to reassure women diagnosed with meningioma that they can file a new Depo-Provera lawsuit in 2026 if they were receiving Depo-Provera injections before this Depo-Provera label change in December 2025 that added the meningioma warning.

The reason a considerable number of Depo-Provera meningioma drug injury lawsuits will likely be filed in 2026 and the couple of years thereafter is that there is a delay, or “latency period”, from the time when a woman has Depo-Provera injections until that woman is diagnosed with meningioma.

Depo-Provera Lawsuits After This December 2025 Depo-Provera Label Change Added Meningioma

Women need to know that (a) if they used Depo-Provera before December 2025, and (b) they received a meningioma diagnosis before or after the December 2025 Depo-Provera label change, then (c) they can file new Depo-Provera lawsuits in 2026 (or later in time) alleging failure to warn about the meningioma side effect.

This is because the new meningioma warning has to do with women being informed about the benefits and risks of a Depo-Provera injection at the time it was received. And, as stated above, before the December 2025 Depo-Provera label change, there was no meningioma warning in any of the previous Depo-Provera drug labels, also known as the Prescribing Information documents.

In summary, here are the two primary factors for whether a woman can file a Depo-Provera meningioma drug injury lawsuit against the responsible pharmaceutical drug companies:

(1)  Before December 2025, the woman must have received at least 1 injection of any of the following:

• Brand name Depo‐Provera 150mg IM Injections (Upjohn, Pharmacia, Pfizer)
• Brand name Depo‐SubQ 104 Provera (Upjohn, Pharmacia, Pfizer)
• An “authorized generic” version of Depo‐Provera manufactured by Pharmacia & Upjohn Company LLC, Greenstone LLC, or Prasco Laboratories

(2)  At some time after that injection, the woman received a diagnosis of some type of meningioma, such as intracranial meningioma, from a medical doctor.

We are handling these Depo-Provera meningioma drug injury lawsuits for women who want to get legal compensation from the responsible pharmaceutical companies.

We point out that these Depo-Provera lawsuits would not be filed against the doctors who prescribed the Depo-Provera injections because the failure to warn about the meningioma side effect was not disclosed until December 2025, when the Depo-Provera label change added a meningioma warning.

We have written previously over on our Drug Injury Watch website about the medical and legal aspects of Depo-Provera meningioma cases:

Meningioma Warning For Depo-Provera Recommended in Europe by Drug Regulator  (February 7, 2025)

Depo-Provera Drug Label Warnings in US Do Not Include Increased Risk of Intracranial Meningioma  (January 30, 2025)

Side Effects of Birth Control: Brain Tumors Related to Depo-Provera Contraceptive Injections  (October 16, 2024)

If you or someone you know has a possible Depo-Provera lawsuit, we suggest submitting a Case Evaluation Form online or calling our office (910-256-2971) to discuss the case facts with drug injury attorney Tom Lamb.

From the Abstract part of this medical journal article, “Deep Venous Thrombosis Within Two Weeks of Initiating Oral Semaglutide (Rybelsus): A Case Report”, we get some information about the Rybelsus blood clots DVT case:

We report the case of a 16-year-old male with mild conventional risk factors for thrombosis [overweight body mass index (BMI) and prolonged sedentary behavior] who developed acute left lower extremity deep venous thrombosis (DVT) within two weeks of initiating [Rybelsus (oral semaglutide)] for weight reduction without medical supervision. He presented with progressive leg pain and swelling, and duplex ultrasonography revealed thrombosis of the distal superficial femoral and popliteal veins….

This case suggests a possible association between [Rybelsus (oral semaglutide)] and venous thrombosis in an adolescent, highlighting the need for careful supervision during off-label use.

We have written previously about the Ozempic, Wegovy, and Rybelsus blood clots side effects of deep vein thrombosis (DVT) and pulmonary embolism (PE):

Semaglutide-Related Blood Clots Cases: Ozempic, Wegovy, and Rybelsus

Deep Vein Thrombosis When Using Wegovy, Rybelsus, or Ozempic

Wegovy / Rybelsus / Ozempic Deep Vein Thrombosis Side Effects

We can assist individuals with a Rybelsus blood clots DVT case if they submit an online Case Evaluation Form or call us at 910-256-2971.

Because there are no warnings about NAION vision loss for Ozempic or Mounjaro in their current drug labels, those drug injury cases would only be filed against these responsible pharmaceutical companies — and not against patients’ doctors.

As regards the Mounjaro and Ozempic NAION vision loss lawsuits that are filed in federal courts, the U.S. Judicial Panel on Multidistrict Litigation (JPML) issued a December 2025 ruling that keeps these NAION lawsuits separate and apart from hundreds of earlier-filed Mounjaro and Ozempic cases involving gastrointestinal side effects.

The new federal court MDL case for the consolidation of Mounjaro and Ozempic NAION vision loss lawsuits is IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy [NAION] Products Liability Litigation, MDL No. 3163.

In addition to Mounjaro and Ozempic, this relatively new MDL No. 3163 lawsuits “consolidation” — which is not the same as a “class action”, but often confused with such — includes NAION cases involving a few other injectable GLP-1 agonist medicines from Eli Lilly (Zepbound) and Novo Nordisk (Wegovy and Rybelsus).

For these NAION vision loss lawsuits, we offer an online case evaluation service that is free and confidential, and without obligation:

Zepbound / Mounjaro Eye Side Effect NAION Case Evaluation Form

Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form

Experienced drug injury lawyer Tom Lamb will review your Case Evaluation Form, and he usually responds to you no later than the next business day.

If you would rather speak with Tom Lamb about your possible NAION eye side effect drug injury lawsuit, call him at 910-256-2971.

We look forward to assisting you or someone you know with a NAION case seeking legal compensation from the pharmaceutical drug company Eli Lilly (Mounjaro and Zepbound) or Novo Nordisk (Ozempic, Wegovy, and Rybelsus).

As background, here are our earlier posts:

• “Andexxa Blood Clots and Clotting-Related Deaths: FDA November 2024” (1/22/2024)
• “Andexxa Blood Clot Cases Before Any AstraZeneca Drug Recall” (1/6/2025)

According to this December 12, 2025, MedPage Today news report, “Anticoagulant Reversal Drug Pulled From U.S. Market“, we learned that Andexxa will be withdrawn from the US market next week, on December 22, 2025.

The pharmaceutical company responsible for Andexxa, AstraZeneca, asserts that this Andexxa recall has to do with “commercial reasons”. However, that December 2025 MedPage Today article, as we had previously, points out Andexxa blood clots that have been associated with Andexxa use:

Safety concerns arose as early as 2016’s ANNEXA-4 initial study presentation, however, when outside observers noted a signal of excess thrombotic events among the study’s [Andessa (andexanet)] users. The clotting issue became more apparent with ANNEXA-I showing more thrombotic events (14.6% vs 6.9%) and more thrombosis-related deaths (2.5% vs 0.9%) comparing [Andessa (andexanet)] versus usual care with a prothrombin complex concentrate (PCC).

Even before this December 2025 Andexxa recall in the US, we had been looking into possible Andexxa blood clot drug injury lawsuits for patients who developed a pulmonary embolism (PE) or deep vein thrombosis (DVT), causing them to be hospitalized or resulting in their death.

For those people, we encourage you to submit an Andexxa Blood Clots Case Evaluation Form online – it is free, confidential, and there is no obligation.

Four people in Denmark who developed serious eye conditions after using popular weight-loss and diabetes drugs Wegovy and Ozempic are entitled to compensation, an independent body ruled Friday.

More than 40 people had sought reimbursement after they said they had developed a serious eye condition as a result of using one of the drugs, both made by Novo Nordisk, according to the Danish Patient Compensation association.

The condition — NAION (non-arteritic anterior ischemic optic neuropathy) — is a lack of blood supply to the optic nerve, which can lead to a loss of vision.

The association said that it had ruled on five cases so far, and found four people who merited compensation….

In Denmark, health authorities generally pay out medical compensation for a drug injury such as NAION linked to Ozempic.  The Danish Patient Compensation association is an independent body that evaluates these types of patient claims on behalf of the government.

Over the past year, we have heard from people with Ozempic vision loss claims who are seeking compensation payments. In the US, those claims would be filed as drug injury lawsuits in the court system.  When successful, the resulting legal compensation payments would be made by the responsible drug company, Novo Nordisk.

Among the liability allegations that would be asserted in the lawsuits for those US Ozempic vision loss claims is Novo Nordisk’s failure to warn that semaglutide has been linked to an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) in several medical studies. The current Ozempic drug label in the US does not have any warnings about NAION.

We are investigating Ozempic vision loss claims for patients who have been diagnosed with NAION, as well as similar cases with the use of Wegovy or Rybelsus, which are two other semaglutide-containing drugs from Novo Nordisk.

Again, these drug injury lawsuits with vision loss claims involving Ozempic, Wegovy, and Rybelsus would be filed against Novo Nordisk for its failure to warn about the increased risk of NAION associated with semaglutide in its current US drug labels for those semaglutide-containing drugs.

If you are interested, you can submit an online Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form. Attorney Tom Lamb reviews each one of these submissions. He evaluates them as possible drug injury lawsuits seeking compensation payments for the person suffering from a loss of vision or blindness due to NAION. This case evaluation service is free and confidential, and without obligation.

(1) Women with at least 4 years of Depo-Provera use; and,

(2) Women who started their Depo-Provera injections after age 31.

As such, those two factors can be viewed as additional risk factors for meningioma side effects associated with Depo-Provera (depot medroxyprogesterone acetate).

That article reporting on a medical study of Depo-Provera meningioma cases in the US can be found in the November 2025 print edition of JAMA Neurology.

From the Results part of this medical journal article’s Abstract:

Use of [Depo-Provera (depot medroxyprogesterone acetate)] had a relative risk of 2.43 (95% CI, 1.77-3.33) for meningioma diagnosis compared with controls. Notably, this risk was confined for patients with longer than 4 years of exposure or starting the prescription at ages older than 31 years.

We point out that these meningioma with Depo-Provera use drug injury lawsuits will not be filed against the women’s doctors who prescribed the Depo-Provera injections. This is because the Depo-Provera drug label in the US does not have any warnings about the increased risk of intracranial meningioma.

A woman diagnosed with an intracranial meningioma while using Depo-Provera or after she stopped using Depo-Provera can submit an Online Case Evaluation Form for a possible Depo-Provera drug injury lawsuit. Alternatively, you can call 910-256-2971 to speak with attorney Tom Lamb about your meningioma with Depo-Provera use situation.

From an October 20, 2025, News Release from the American Academy of Ophthalmology, “Do GLP-1 Drugs like Ozempic Cause or Prevent Vision Loss?“:

Researchers in an international collaboration across the University of Ottawa Eye Institute, University of Toronto, McMaster University, and Doheny Eye Institute UCLA conducted one of the largest global studies on the topic to date. Using data from the World Health Organization’s global database of drug safety reports, the authors analyzed data on 117,173 patients with diabetes taking semaglutide [Ozempic, as well as Rybelsus and Wegovy](GLP-1 drugs), empagliflozin, exenatide, tirzepatide, or insulin.

Results showed that people using GLP-1 drugs were 68.6 times more likely to develop NAION and eight times more likely to develop diabetic retinopathy than those taking empagliflozin, exenatide, insulin or metformin. The analysis found no significant association between tirzepatide (the active ingredient in other GLP-1 medications including Mounjaro and Zepbound) and NAION or diabetic retinopathy. [Emphasis added]

The American Academy of Ophthalmology (AAO) is the world’s largest association of eye physicians and surgeons.  So it makes this “Ozempic NAION rate higher” announcement significant.

The earlier Ozempic NAION rates, which were significantly lower, had already resulted in drug injury lawsuits being filed by patients against the responsible pharmaceutical company, Novo Nordisk.

Here is an April 2025 Drug Injury Watch article that you can read to learn more about lawsuits involving NAION, titled “Ozempic Vision Loss Lawsuits Have Been Filed by Patients Against Novo Nordisk“. That article lists some of the legal liability allegations regarding Novo Nordisk’s actions and failures. It also points out that the current Ozempic drug label does not warn about NAION as a possible eye side effect that can cause vision loss or blindness.

One wonders whether a medical study with the Ozempic NAION rate higher, as announced by this October 2025 AAO News Release, might increase the number of Ozempic vision loss lawsuits.

If you are interested in a possible Ozempic lawsuit seeking legal compensation for your NAION eye side effect, you can submit an Online Case Evaluation Form. It is free, confidential, and there is no obligation. We will reply to you no later than the next business day.

Some of the allegations contained in the lawsuits for Dupixent cancer cases are:

1. Defendants Regeneron and Sanofi knew or should have known of the potential of Dupixent to exacerbate or accelerate pre-existing T-cell lymphoma, including cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL), or increase susceptibility to its development.
2. Defendants failed to adequately test Dupixent to investigate the risks, including the potential of exacerbating pre-existing T-cell lymphoma or increasing susceptibility to its development.
3. Defendants failed to warn physicians and patients that Dupixent should not be prescribed or administered to patients with confirmed or suspected T-cell lymphoma, including CTCL and PTCL.

As background, here is some basic medical information relevant to these Dupixent cancer cases:

• There are several types of T-cell lymphoma, including cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL).
• CTCL is a T-cell lymphoma that begins in the skin. Mycosis fungoides and Sézary syndrome are the two most common subtypes of CTCL.
• PTCL refers to systemic T-cell lymphomas that are found in the lymph nodes, other organs, and the blood. Also, some types involve the skin.
• T-cell lymphomas, both CTCL and PTCL, are a subtype of non-Hodgkin lymphoma (NHL).

We are currently investigating possible Dupixent cancer cases for patients who were diagnosed with one of the following medical conditions, some time after they started using Dupixent:

• T-cell lymphoma
• cutaneous T-cell lymphoma (CTCL)
• peripheral T-cell lymphoma (PTCL)
• Mycosis fungoides
• Sézary syndrome

For individuals with a Dupixent-related cancer case, we encourage them to submit a Dupixent Cancer Case Evaluation Form online or call 910-256-2971 to discuss their potential case with attorney Tom Lamb.